ARQT · Insider Trading
Arcutis Biotherapeutics, Inc. Common Stock
Every open-market purchase and sale reported by ARQT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Todd Watanabe | See Remarks | Sell | −4,377 | −$139.47K |
| 2026-11-04 | Patrick Burnett | EVP, Chief Medical Officer | Sell | −943 | −$30.05K |
| 2026-11-04 | Masaru Matsuda | EVP, Chief Legal Officer | MIXED | −1,219 | −$1.27M |
| 2026-10-28 | Robert A Scott | Director | A | +2,819 | — |
| 2026-10-19 | Howard G. Welgus | Director | MIXED | −634 | −$94.87K |
| 2026-09-18 | Masaru Matsuda | See Remarks | Sell | −3,674 | −$91.85K |
| 2026-09-17 | Howard G. Welgus | Director | MIXED | −634 | −$81.90K |
| 2026-09-10 | Masaru Matsuda | See Remarks | Sell | −9,989 | −$249.99K |
| 2026-08-28 | Terrie Curran | Director | MIXED | — | −$638.94K |
| 2026-08-24 | Terrie Curran | Director | MIXED | — | −$19.86K |
| 2026-08-21 | Patrick Burnett | See Remarks | Sell | −1,697 | −$45.82K |
| 2026-08-19 | Howard G. Welgus | Director | MIXED | −634 | −$91.36K |
| 2026-08-13 | Patrick Burnett | See Remarks | MIXED | — | −$340.30K |
| 2026-08-05 | Patrick Burnett | See Remarks | Sell | −955 | −$24.94K |
| 2026-08-05 | Todd Watanabe | See Remarks | Sell | −4,375 | −$114.26K |
| 2026-08-05 | Masaru Matsuda | See Remarks | Sell | −1,230 | −$32.12K |
| 2026-07-17 | Christopher Peetz | Director | A | +4,315 | — |
| 2026-07-17 | Howard G. Welgus | Director | MIXED | −634 | −$94.81K |
| 2026-06-17 | Sue-Jean Lin | Director | Sell | −4,946 | −$120.59K |
| 2026-06-17 | Howard G. Welgus | Director | MIXED | −635 | −$83.81K |
| 2026-06-12 | Patrick J Heron | Director | — | — | — |
| 2026-06-09 | Patrick J Heron | Director | A | +5,778 | — |
| 2026-06-09 | Amit Munshi | Director | A | +5,778 | — |
| 2026-06-09 | Keith R Leonard | Director | A | +5,778 | — |
| 2026-06-09 | Howard G. Welgus | Director | A | +5,778 | — |
| 2026-06-09 | Neha Krishnamohan | Director | A | +5,778 | — |
| 2026-06-09 | Halley E Gilbert | Director | A | +5,778 | — |
| 2026-06-09 | Terrie Curran | Director | A | +5,778 | — |
| 2026-06-09 | Sue-Jean Lin | Director | A | +5,778 | — |
| 2026-05-13 | Latha Vairavan | SVP Chief Financial Officer | Sell | −435 | −$9.16K |
| 2026-05-13 | Patrick Burnett | See Remarks | Sell | −222 | −$4.67K |
| 2026-05-06 | Masaru Matsuda | See Remarks | Sell | −8,256 | −$192.42K |
| 2026-05-06 | Latha Vairavan | SVP Chief Financial Officer | Sell | −1,341 | −$31.66K |
| 2026-05-06 | Patrick Burnett | See Remarks | Sell | −684 | −$16.15K |
| 2026-05-06 | Todd Watanabe | See Remarks | Sell | −3,172 | −$74.89K |
| 2026-05-05 | Howard G. Welgus | Director | Sell | −7,144 | −$164.22K |
| 2026-04-03 | Howard G. Welgus | Director | Sell | −10,000 | −$238.80K |
| 2026-03-04 | Howard G. Welgus | Director | Sell | −10,000 | −$256.52K |
| 2026-03-04 | Keith R Leonard | Director | MIXED | — | −$671.96K |
| 2026-03-03 | Larry Todd Edwards | See Remarks | MIXED | +26,313 | −$92.85K |
| 2026-03-03 | Latha Vairavan | SVP Chief Financial Officer | MIXED | +24,147 | −$71.84K |
| 2026-03-03 | Todd Watanabe | See Remarks | MIXED | +64,651 | −$940.53K |
| 2026-03-03 | Masaru Matsuda | See Remarks | MIXED | +24,942 | −$313.88K |
| 2026-03-03 | Patrick Burnett | See Remarks | MIXED | +40,463 | −$158.32K |
| 2026-02-04 | Howard G. Welgus | Director | Sell | −10,000 | −$250.48K |
| 2026-02-04 | Patrick Burnett | See Remarks | Sell | −13,469 | −$346.45K |
| 2026-02-04 | Latha Vairavan | SVP Chief Financial Officer | Sell | −1,320 | −$33.66K |
| 2026-02-04 | Todd Watanabe | See Remarks | Sell | −19,833 | −$505.71K |
| 2026-02-04 | Larry Todd Edwards | See Remarks | Sell | −2,052 | −$52.32K |
| 2026-02-04 | Masaru Matsuda | See Remarks | Sell | −40,638 | −$1.03M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Bhaskar Chaudhuri | Director | 917,807 | $23.35M |
| Todd Watanabe | See Remarks | 738,236 | $18.78M |
| Christopher Peetz | Director | 191,815 | $4.88M |
| David Joseph Topper | Chief Financial Officer | 182,774 | $4.65M |
| Larry Todd Edwards | See Remarks | 175,281 | $4.46M |
| Patrick Burnett | EVP, Chief Medical Officer | 116,649 | $2.97M |
| Masaru Matsuda | EVP, Chief Legal Officer | 111,289 | $2.83M |
| Latha Vairavan | SVP Chief Financial Officer | 85,978 | $2.19M |
| Howard G. Welgus | Director | 64,926 | $1.65M |
| Patrick J Heron | Director | 59,661 | $1.52M |
| Keith R Leonard | Director | 29,651 | $754.32K |
| Halley E Gilbert | Director | 27,901 | $709.80K |
| Neha Krishnamohan | Director | 27,901 | $709.80K |
| Sue-Jean Lin | Director | 27,567 | $701.30K |
| Terrie Curran | Director | 23,526 | $598.50K |
| Amit Munshi | Director | 9,799 | $249.29K |
| Robert A Scott | Director | 2,819 | $71.72K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ARQT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.